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Abstract
Introduction:  Obstructive  sleep  apnea  (OSA)  affects  approximately  1--3%  of  pediatric  population
and is  associated  with  signiﬁcant  morbidity.  As  adenotonsillar  hypertrophy  (ATH)  is  its  primary
cause in  children,  elective  adenotonsillectomy  is  the  ﬁrst  treatment  of  choice.  Noninvasive
ventilation  (NIV)  has  been  increasingly  considered  as  an  option,  mainly  for  children  with  complex
diseases,  ineligible  or  waiting  for  surgeries,  or  after  surgery  failure.
Objectives:  To  describe  the  experience  in  the  management  of  children  with  complex  OSA,  and
to evidence  the  feasibility  and  advantages  of  NIV.
Methods:  This  was  a  retrospective  cohort  study  of  68  children  on  NIV,  in  whom  complex  OSA
was the  main  indication  for  ventilation,  in  a  Pediatric  Respiratory  Unit  at  a  University  Hospital
between January  1997  and  March  2012.  Demographic  and  clinical  data  were  collected  on  the
underlying diagnosis,  therapeutic  interventions  prior  to  NIV,  NIV  related  issues  and  outcome.
Results: Forty  (59%)  children  were  male,  median  age  at  starting  NIV  was  6  years  and  7  months,
with interquartile  range  (IQR)  of  15--171  months.  Twenty-two  (32%)  were  infants  and  25  (37%)
adolescents.
The most  common  diagnosis  was  congenital  malformations  and  genetic  disorders  in  34  (50%)
patients. Nine  patients  had  cerebral  palsy,  8  were  post  treatment  for  central  nervous  system
tumors and  6  had  inborn  errors  of  metabolism.  Three  children  had  ATH  and  three  obesity.  The
majority  of  patients  (76%)  had  exclusively  obstructive  OSA  and  started  CPAP.  Ten  patients  had
minor complications.  Twenty-two  patients  stopped  NIV  due  to  clinical  improvement,  8  were
non-compliant  and  8  patients  died.  NIV  median  duration  was  21.5  months  (IQR:  7--72).
Conclusions:  NIV  is  feasible  and  well  tolerated  by  children  with  OSA  associated  with  complex
disorders,  and  has  been  shown  to  have  few  complications  even  in  infants  and  toddlers.
© 2013  Sociedade  Portuguesa  de  Pneumologia.  Published  by  Elsevier  España,  S.L.  All  rights
reserved.
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PALAVRAS-CHAVE
Ventilac¸ão  não
invasiva;
Apneia  obstrutiva  do
sono;
Crianc¸as
Ventilac¸ão  não-invasiva  em  apneia  obstrutiva  do  sono  complexa  --  Uma  experiência
de  15  anos  de  um  centro  pediátrico  terciário
Resumo
Introduc¸ão:  A  apneia  obstrutiva  do  sono  (OSA)  afeta  aproximadamente  1--3%  da  populac¸ão
pediátrica  e  está  associada  com  uma  morbidade  signiﬁcativa.  Como  a  hipertroﬁa  adenoton-
siliana (ATH)  é  a  sua  principal  causa,  a  adenocele  eletiva  é  a  primeira  opc¸ão terapêutica.  A
ventilac¸ão não  invasiva  (VNI)  tem  sido  cada  vez  mais  considerada  como  uma  opc¸ão,  princi-
palmente  para  as  crianc¸as  com  doenc¸as  complexas,  inelegíveis,  à  espera  de  cirurgias  ou  após
falência do  tratamento  cirúrgico.
Objetivos:  Descrever  a  experiência  no  tratamento  de  crianc¸as  com  OSA  complexo  e  avaliac¸ão
da viabilidade  e  das  vantagens  do  NIV.
Métodos:  Estudo  de  coorte  retrospetivo  de  68  crianc¸as  em  NIV,  onde  o  complexo  OSA  foi  a
principal indicac¸ão  para  ventilac¸ão,  numa  Unidade  Respiratória  Pediátrica  de  um  Hospital  Uni-
versitário  entre  janeiro  de  1997  e  marc¸o de  2012.  Os  dados  demográﬁcos  e  clínicos  recolhidos
englobaram  o  diagnóstico  subjacente,  as  intervenc¸ões  terapêuticas  prévias  à  NIV,  as  intercor-
rências relacionadas  com  a  NIV  e  a  evoluc¸ão  clínica.
Resultados:  Quarenta  (59%)  crianc¸as  eram  do  sexo  masculino,  idade  média  no  início  da  NIV  foi
de 6  anos  e  7  meses,  com  intervalo  interquartil  (IQR)  de  15--171  meses.  Vinte  e  duas  (32%)  eram
crianc¸as e  25  (37%)  adolescentes.
O diagnóstico  mais  comum  foram  as  malformac¸ões  congénitas  e  as  doenc¸as  genéticas  em  34
(50%) pacientes.  Nove  pacientes  tiveram  paralisia  cerebral,  8  sequelas  de  pós-tratamento  para
tumores do  sistema  nervoso  central  e  seis  sofriam  de  erros  inatos  do  metabolismo.  Três  crianc¸as
sofriam de  ATH  e  três  de  obesidade.  A  maioria  dos  pacientes  (76%)  sofria  exclusivamente  de
OSA obstrutiva  e  iniciou  CPAP.  Dois  doentes  sofriam  complicac¸ões  menores.  Vinte  e  dois  doentes
pararam o  NIV,  devido  a  melhoria  clínica,  8  eram  não-conformes  e  8  morreram.  A  durac¸ão  média
do NIV  foi  21,5  meses  (IQR:  7--72).
Conclusões:  A  NIV  é  uma  terapia  viável  e  bem  tolerada  em  crianc¸as  com  OSA  e  doenc¸as  com-
plexas, com  poucas  complicac¸ões,  incluíndo  em  bebés  e  crianc¸as  pequenas.
sa  d
i
t
c
a
d
v
M
A
c
w
E
i
o
s
v
t
i
u
n© 2013  Sociedade  Portugue
direitos reservados.
Introduction
Pediatric obstructive sleep respiratory disorder has a broad clinical
spectrum, from simple snoring to the most severe obstructive sleep
apnea (OSA).
OSA occurs in 1--3% of children,1--3 and is deﬁned by airway
obstruction, either partial and prolonged or complete and inter-
mittent, interfering with sleep patterns and ventilation.
Adenotonsillar hypertrophy (ATH) is the most frequent cause in
children, but craniofacial malformations, as well as neuromuscular
diseases and obesity have been increasingly considered.4
In childhood, OSA has important repercussions on somatic
growth, the cardiovascular system and neurocognitive
development.5--7 Early diagnosis and intervention are essential to
prevent complications and improve quality of life.8,9
Identiﬁcation of clinical criteria (respiratory pauses, hard or
noisy breathing or excessive daytime somnolence) and predisposing
clinical conditions10 support the diagnosis of OSA, but polysomno-
graphy (PSG) is currently considered the gold standard.11,12
As the main cause of OSA in childhood is ATH, adenoton-
sillectomy is the most commonly recommended treatment for
uncomplicated cases.10,13,14 There is, however, growing evidence of
surgery failure15 and there are a signiﬁcant number of children with
craniofacial defects who need alternative therapies. These children
represent a group with complex OSA, requiring innovative surgical
and medical approaches.
In children with chronic conditions or complex OSA, NIV has
been increasingly used since 1984,16,17 when surgery is contraindi-
cated or ineffective, or as a supportive treatment until appropriate
stage for surgical intervention, allowing for clinical stabilization and
growth.18--20
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NIV efﬁcacy and tolerance in children have been reported
n a few studies18,21,22 and clearly the experience of qualiﬁed
eams with appropriate support facilities warrants high quality
are.10,23,24
The main objective of this study is to describe our experience in
 tertiary Portuguese pediatric center in the management of chil-
ren with complex OSA, for whom noninvasive positive-pressure
entilation was an effective therapeutic alternative.
ethods
 retrospective  case  series  study  was  performed  through
hart  review  of  all  cases  of  children  submitted  to  NIV,  in
hich  complex  OSA  was  the  main  indication  for  ventilation.
ligible  cases  were  identiﬁed  from  internal  clinical  database
n  the  period  of  January  1997  to  March  2012.  Children  with
ther  indications  for  NIV  were  excluded.
Demographic  data  were  collected,  including  primary  and
econdary  clinical  diagnoses,  sleep  studies  results,  modes  of
entilation,  adherence,  complications  and  efﬁcacy  related
o  NIV.  Clinical  data  concerning  sleep  disordered  breath-
ng  including  difﬁcult  or  noisy  breathing,  respiratory  pauses,
nsettled  sleep,  excessive  sweating,  excessive  daytime  som-
olence,  morning  headache  and  failure  to  thrive  were
ssessed.  All  patients  underwent  sleep  studies:  continuous
ranscutaneous  monitoring  of  O2 and  CO2 (Tc  CO2),  comple-
ented  with  capillary  blood  gases  from  the  begining  through
004,  on  an  inpatient  basis,  formal  sleep  studies  at  the  sleep
1 I.C.  Girbal  et  al.
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According to information provided by the parents, subjective
evidence of adherence was considered good in 53 (78%) children.
No objective measures of adherence were applied.
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aboratory  (cardio-respiratory  studies  (CRS)  from  2004  and
SG  after  2008).
OSA  was  diagnosed  based  on  clinical  signs  of  sleep
isordered  breathing  as  described  ahead  and,  whenever
vailable,  by  an  apnea/hypopnea  index  (AHI)  ≥  1.
OSA  plus  hypoventilation  syndrome  was  considered  when
here  was  hypoventilation  associated  to  obstructive  events
Tc  CO2median  >  45  mmHg  or  morning  p  CO2 >  45  mmHg).
For  PSG  and  CRS,  average  saturation  and  AHI  were  col-
ected.  An  AHI  ≥  1/h  was  considered  abnormal.
In  this  study  NIV  was  deﬁned  as  any  noninvasive  ven-
ilatory  support  delivered  by  ﬂow  generators  suitable  for
mbulatory  use,  whenever  CPAP  or  bi-level  positive  airway
ressure  (BiPAP)  was  applied.  The  decision  on  ventilatory
odality  relied  on  the  presence  of  isolated  OSA  or  associ-
ted  hypoventilation,  CPAP  was  the  choice  in  the  former
ases  and  BiPAP  in  the  latter.  BiPAP  was  also  used  in  isolated
SA  to  increase  tolerance  when  high  pressures  were  needed.
In  all  patients  NIV  was  started  in  the  pediatric  respira-
ory  ward  or  in  the  pediatric  sleep  laboratory,  depending
n  the  clinical  status  of  the  patient  and  availability.  In  the
ard,  pressures  were  progressively  increased  until  elimina-
ion  of  snoring  and  improvement  in  the  respiratory  pattern
nd  pulse  oximetry.  In  the  laboratory,  the  pressures  were
itrated  according  to  international  guidelines.11--13 In  both
ettings  the  initial  pressure  was  always  above  4  cm  H2O  and
esulted  in  the  elimination  of  respiratory  events  and  normal-
zation  of  pulse  oximetry,  TcCO2 and  morning  blood  gases.
Families  and  patients  underwent  training  in  mask  ﬁtting,
quipment  management  and  adverse  effects  prevention.
heir  ability  to  maintain  NIV  at  home  was  evaluated.  A  24-
 phone  number  was  available  for  additional  information.
 ﬁrst  follow-up  appointment  was  booked  for  2--3  weeks
fter  starting  following  NIV.
Adherence  to  treatment  was  evaluated  by  subjective
stimation  of  daily  NIV  hours,  based  upon  information  pro-
ided  by  caregivers  registered  in  the  clinical  ﬁle.  Adherence
as  classiﬁed  as  insufﬁcient  where  the  NIV  time  was  less
han  3  hours  per  night.
The  recording  and  analysis  of  data  were  performed  on
PSS® statistics  for  Windows®,  version  19.0©. Quantitative
bsolute  and  relative  data  are  expressed  as  mean  and
tandard  deviation  or  median  and  interquartile  range  (IQR)
or  data  not  normally  distributed.
esults
uring the study period, 68 children with OSA started NIV, repre-
enting 41.2% of all the pediatric patients under NIV program at the
ediatric Respiratory Unit.
Forty (59%) patients were male, median age at starting NIV was
 years and 7 months (IQR: 15--171 months).
Two main age distribution groups were identiﬁed, 22(32%)
nfants and 25 (37%) adolescents (Fig. 1).
A progressive increase in the number of patients entering the
rogram yearly was found, with 61.7% of them starting NIV in 2005
r later (Fig. 2).
The most frequent diagnoses were congenital malformations and
enetic disorders in 34 (50%) patients, cerebral palsy in 9 (13%) and
nborn errors of metabolism in 6 (9%). Eight (12%) patients were
eferred to the center because of OSA after treatments for cen-
ral nervous system (CNS) tumors. Obesity and ATH were found asFigure  1  Age  distribution  at  NIV  start.
primary diagnosis for 3 patients each (4%). The complete distribu-
ion of the pathologies is illustrated in Table 1.
Comorbidities were present in 38 (56%), gastro-esophageal reﬂux
GER) in 17, obesity in 13, rhinitis in 7 and asthma in 5 patients.
ome patients had association of comorbidities.
In 52 (76%) patients respiratory sleep disorders were considered
xclusively obstructive and CPAP was prescribed.
Sixteen patients (24%) started on bilevel NIV, in four to increase
olerance when high pressures were needed to surpass the airway
bstruction and in twelve patients because of mixed ventilatory
onditions (OSA plus hypoventilation syndrome): 5 with secondary
besity (2 Prader--Willi, 2 trisomy 21, 1 CNS tumor) and the rest
ecause of signiﬁcant hypotonic disorder or restrictive respiratory
attern.
In all patients the interface for positive pressure delivering was
asal mask or prongs.
NIV was started electively in 42 (62%) patients and in acute set-
ing in 26 (38%) after respiratory exacerbation or as transition from
nvasive ventilation, most transferred from Pediatric or Neonatal
ntensive Care Units.
NIV was started without previous ear, nose and throat (ENT) or
raniofacial surgery in 55 (81%) patients. Nine of them had surgery
uring follow-up, and after intervention it was possible to stop ven-
ilation in 5. Thirteen children (19%) started NIV after ENT surgery
ailure.
Prior to the implementation of NIV, 33 (49%) patients per-
ormed a formal sleep study (PSG or CRS). These results are shown
n Table 2.
The median duration on NIV (data from 62/68 patients) was 21.5
IQR: 7--72) months. Thirty (44%) patients are still on NIV. In 22
32%) NIV was successfully withdrawn, 17 (77%) of which due to
pontaneous resolution of clinical condition and 5 after relevant
urgery. Eight patients (12%) died as result of their main diagno-
is: CNS tumor,3 mucopolysaccharidosis,2 Prader--Willi syndrome,1
erebral palsy1 and tongue sarcoma.1 Eight patients (12%) were lost19
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Figure  2  Annual  distribution  at  NIV  starting  point.
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Table  1  Distribution  of  patients  according  to  primary  diagnosis,  presence  of  associated  hypoventilation  and  age  at  NIV  start.
Nosologic  group  Patients  (N  =  68)  OSA  plus  hypoventilation
syndrome
Age  at  NIV  start  in  months
n (%)b n  (%)b Median  (IQR)
Congenital  malformations/genetic  disorders  34  (50)  7  (10)  42.5  (5--144)
Prader--Willi  syndrome  6  2  176  (158--187)
Pierre--Robin  syndrome  5  0  1  (0--2)
Trisomy 21  5  2  120  (46--180)
Craniofacial  malformationa 10  0  40  (7--45)
Airway malacia  5  0  13  (2--15)
Other 3  3  60  (40--96)
Cerebral palsy 9  (13) 2  (3) 168  (89--173)
Central nervous  system  tumor 8  (12) 1  (1.5) 171  (94--180)
Inborn errors  of  metabolism  6  (9)  2  (3)  59  (20--135)
Mucopolysaccharidosis  5  2  59  (46--156)
Gaucher disease  1  0  2
Adenoid/tonsil  hypertrophy  3  (4)  0  15  (12--31)
Obesity 3  (4)  0  166  (154--194)
Others 5  (8)  0  106  (85--110)
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pIncluding choanal atresia, craniosynostosis, pycnodysostosis, a
b All percentages refer to the total number of patients (N = 68).
Minor complications of NIV were recorded in ten (14.7%)
patients: local skin irritation was reported in 3, conjunctivitis in
4 and skin breakdown in 3. In two (3%) slight facial deformation was
found.
All patients with sustained NIV had clinical improvement, as
reported in clinical ﬁles.
Twenty-nine (43%) patients performed PSG or CRS after the
implementation of NIV, in order to monitor their response to treat-
ment. The results are shown in Table 2.
Discussion
Our study shows, as other series have done,24--27 that OSA is a
common indication for NIV in pediatric patients. This therapeutic
support has been increasingly used in selected pediatric popula-
tions, as our data also conﬁrm, with most of the patients (61.7%)
starting NIV in 2005 and thereafter.
There was a wide age range distribution for starting NIV,
clearly related to the different timings of ventilation support
needed for different disorders. We found a signiﬁcant number of
infants, being about a third of the patients. In this age group air-
way malacia and Pierre--Robin syndrome were the most frequent
diseases found, usually with transient NIV and a good prognosis.
b
f
s
f
Table  2  Formal  sleep  studies  before  and  after  NIV.
Formal  sleep  study  Patients  Apnea/
n (%)a Median  
Before  non-invasive  ventilation  33  (49)
Polysomnography  23  (34)  9.7  (5.8
Cardiorespiratory  study  10  (15)  8.6  (3.3
After non-invasive  ventilation  29  (43)
Polysomnography  25  (37)  0.3  (0--2
Cardiorespiratory  study  4  (6)  0.6  (0.3
IQR: interquartile range.
a The percentages refer to the total number of patients in the study roplasia, Charge Syndrome.
his emphasizes the fact that NIV is being increasingly used in small
hildren, with good tolerance and efﬁcacy8,22,28 allowing somatic
rowth to occur and in some cases avoiding tracheostomy.29As
escribed in other series, we veriﬁed a slight male predominance
58.8%).30,31
Half of patients had congenital malformations or genetic disor-
ers as the main cause of OSA. This multiplicity of diagnosis has been
reviously described by others,8,9,23,24 the most relevant features
eing craniofacial malformations and airway malacia. The reason
or opting for NIV in these complex patients is easily understood,
s most of these disorders have several simultaneous factors con-
ributing to OSA, as well as isolated adenoid hypertrophy, and hence
ave suboptimal results or no indication for surgical approach. The
ccumulated experience with this heterogeneous group of patients
epends on the speciﬁcity of our institution, a tertiary university
ospital, where a multidisciplinary approach is possible and often
arrants support for these complex patients with multiple medical
eeds. CPAP is very helpful in isolated OSA, improving the quality
f sleep, daytime functioning and caregiver concern32 but BiPAP is
referred when there is associated hypoventilation. As described
efore,32 the main beneﬁts obtained in these patients could be dif-
erent from otherwise healthy children and focused on palliation of
ymptoms and quality of life improvement, for patients and their
amilies.
hypopnea  index  (AHI)  Average  peripheral  saturation
(IQR)  Median  (IQR)
--18.8)  94.5%  (87.9--96.0)
--16.3)  96%  (93.8--96.8)
.8)  97%  (95.2--97.9)
--2.5)  97.5%  (97.8--98.2)
(N = 68).
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Three patients had isolated ATH for whom NIV was a transient
upport used to stabilize the patients while waiting for surgery, as
escribed in the literature.33
Three patients were started on NIV because of primary obe-
ity, which is increasingly associated to childhood OSA34 and often
 cause of persistent OSA after adenotonsillectomy.16
Implementation of CPAP effectively controlled OSA in
2 patients.  In the rest, BiPAP was started. Both forms are
ffective in pediatric OSA,35 and the option is determined by the
xistence of an OSA plus hypoventilation syndrome or the need for
igh ventilatory pressures.
Comorbidities, present in more than half of our patients, either
lone or in association, are relevant issues. Their identiﬁcation and
reatment are essential because they can interfere with therapeu-
ic choices, adhesion and adverse events of treatment.36 Obesity
s the main cause of OSA in adult population, and it also plays a
elevant role in childhood OSA, often being responsible for failure
o respond to surgical treatment in children without other con-
ributing factors.37 As shown in this series, overweight children and
dolescents are a relevant group, including simple and secondary
besity, and in both situations a dietary plan should be part of the
herapeutic approach.38
GER or rhinitis must be actively sought and should be medi-
ally controlled. Speciﬁcally the treatment of allergic rhinitis is an
djuvant measure in controlling AOS,38 and rhinitis can also inter-
ere with NIV compliance, worsening nasal obstruction and mucosal
ryness, frequent side effects associated to NIV.
The gold-standard for OSA diagnosis is the PSG. However, if not
eadily available, alternative tests like pulse oximetry11 may be
ndicated. This was the method used in our setting until 2004. From
his date on, the existence of CRS and later, of PSG (from 2008) have
llowed for a more accurate monitoring for NIV management.
The reason why less than half of the patients33 performed a
ormal sleep study before implementing NIV (23 PSG and 10 CRS),
esides availability, is due to a signiﬁcant number of children start-
ng treatment in a respiratory exacerbation and hence without
revious studies.
In fact in our population NIV was started in a non-elective man-
er in 38% of patients, who needed this support to deal with critical
SA and impending respiratory failure.
After starting treatment, clinical improvement was recorded in
very child, and withdrawal was feasible in 22 (32%). Over a third
43%) of our population performed a formal sleep study to monitor
heir response to treatment.
Unlike other pediatric groups with NIV indication, such as neuro-
uscular patients, some patients with OSA are expected to improve
s the result of somatic growth or surgery (when NIV is used as a
emporary bridge to the procedure).22
In four of the eight deceased patients, with oncologic diseases,
IV was started to control OSA and also as a palliative measure,
mproving comfort and decreasing hospital stay. Even if it was not
nitially the main objective, these patients beneﬁted from greater
linical stability, reducing the burden for themselves and their fam-
lies. In the pediatric setting, we have to consider NIV as part of
 palliative care plan, in which the objective is not the cure but
he preservation of comfort and decreasing suffering for both the
atient and the family.9,23,39
Adherence to treatment is an important issue in the assessment
f NIV in children being closely related to the acceptance and tol-
rability of the mask and to early detection of minor skin lesions.40
 careful mask ﬁtting was carried out with the patients, allowing
hem to choose the most comfortable.
Another very important issue on adherence to treatment is
ducation. Families require appropriate training to be able to
rovide care for the child at home,41 so teaching the caregivers
and when possible, the child) about practical issues, main goals and
onsequences of withdrawal of the treatment are essential for the
uccess of NIV. The adherence was considered good in over twoI.C.  Girbal  et  al.
hirds of our population, but objective measurements of adherence
ere lacking; hence the data cannot be accurately interpreted.
We registered an abandon rate of 12%, which we  considered
igh, but still lower than that described in the literature. Mar-
us et al.42 demonstrated that both methods (CPAP and BiPAP) are
ighly effective, but over a third of their patients had abandoned
reatment at 6 months follow-up.
The main limitation of our study is its retrospective design,
hich limited the availability of some data and prevents a uniform
pproach for each patient.
onclusion
his study described a complex group of patients, in whom NIV was
sed as an option to treat OSA. We  demonstrated its feasibility with
 high success rate, documented few complications, and found this
reatment to be well-tolerated and effective in the management
f OSA, even in toddlers. As other groups have already shown, the
ptimal care for these patients can only be given in qualiﬁed spe-
ialized centers23,24 because the management of these complex
atients requires an holistic understanding of the diagnosis, tech-
ology involved in diagnosis and therapy, prognosis and long-term
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